Physician profile
Steven J Smith
NPI 1306160031
$5,346.00
in general payments reported to CMS, 2019-2025
15 companies · $3,253 in 2025
The $3,253 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $16.38 · 2022: $51.12 · 2023: $646 · 2024: $1,270 · 2025: $3,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,813 · Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,812.50 |
| Food and Beverage | $357.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $4,812.50 | 2023-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Abbvie INC. | $170.45 | 2022-2025 | Qulipta, Ubrelvy |
| Eisai INC. | $56.76 | 2019-2024 | |
| Fresenius USA Manufacturing, INC. | $51.73 | 2025 | |
| Neurelis, INC. | $34.96 | 2023 | Valtoco |
| Viiv Healthcare Company | $33.58 | 2025 | Cabenuva, Apretude |
| Assertio Therapeutics, INC. | $33.09 | 2019 | |
| Dynavax Technologies Corporation | $29.78 | 2023 | Heplisav-B |
| Merck Sharp & Dohme LLC | $24.78 | 2024 | |
| Melinta Therapeutics, LLC | $24.24 | 2022 | |
| Lundbeck LLC | $18.37 | 2019 | |
| Greenwich Biosciences, INC. | $16.38 | 2020 | |
| Pfizer INC. | $13.96 | 2019 | |
| Ucb, INC. | $13.33 | 2019 | |
| Lilly USA, LLC | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.